Formycon AG
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Formycon AG
Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.
/ 
Frequently asked questions
To buy Formycon AG stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Formycon AG by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Formycon AG is FYB:xetr. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Formycon AG has its primary listing on Deutsche Börse (XETRA). You can trade Formycon AG with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Formycon AG is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Formycon AG as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Formycon AG.